Study for Comparing The Pharmacokinetics of A Pregabalin Controlled Release Tablet 300mg With Immediate Release Formulation and to Assess the Effect of High Fat Diet in Healthy Male Subjects

A Randomized, Open-label, 3-way Crossover Clinical Trial to Compare The Pharmacokinetics of A Pregabalin Controlled Release Tablet 300mg With Immediate Release Formulation and to Assess the Effect of High Fat Diet in Healthy Male Subjects

The purpose of this study is to:

1. Compare the pharmacokinetics profiles of pregabalin sustained release tablet (300mg) to immediate release capsule(150mg * 2).
2. Evaluate the effectiveness of food to pharmacokinetics profile of Pregabalin sustained release tablet.

Inclusion Criteria:

• 19~44 aged healthy adult.
• someone tho has at least 50kg body weight and ideal body weight ±20%

Exclusion Criteria:

• someone has acute symptom at screening phase
• someone has any disease or symptoms which is clinically significant
• someone had been determined during healthy examination in screening period
• AST or ALT > 1.25 times than normal
• Total bilirubin > 1.5 times than normal
• someone who has a history of allergy, anaphylaxis, drug abuse or misuse.
• someone who had enrolled to other clinical trial within the last 60 days.
• someone who had donated blood within the last 60 days.
• someone who can't take a meal derived from this trial.
• someone who has taken abnormal meals like which can affect to drug ADME
• someone who has taken other ETC drugs or oriental drugs within the last 14 days, Or OTC drugs within the last 7 days
• someone who has taken caffein continuously (coffee or green tea more than 5 cups per a day) or took caffein since 24hours before.
• someone who has taken alcohol more than 30g/day or smoked more than 10 piece of tobacco/day.
• someone who has galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption.